Table 1.
Age | Sex | FNA/ core needle biopsy | Tumor size | Adverse factor | Treatment | Follow up/outcome | p40/p63 expression | other | |
---|---|---|---|---|---|---|---|---|---|
Adapa et al. [4] | 9 | F | Ewing sarcoma | 6.0 cm | Lymph node metastasis | Chemotherapy, surgery, radiotherapy | 6 years, ANED | N/A | |
Eloy et al. [11] | 42 | F | Follicular tumor | 2.5 cm | Vascular invasion | Total thyroidectomy | 38 months, ANED | Positive | CEFTE |
Maldi et al. [6] | 66 | M | Malignant tumor of possible neuroectodermal origin | 4.5 cm | Vascular invasion | Total thyroidectomy, no chemotherapy or radiotherapy | 8 months/ AWED | Focal expression | |
Chirila et al. [7] | 48 | M | Giant B-cell non-Hodgkin lymphoma | 10 cm | Positive surgical margins | CHOP (initial diagnosis of B cell non Hodgkin lymphoma), followed by etoposide and carboplatin | 1 month, died from brain metastasis | N/A | No validation of EWSR1 fusion |
Chan et al. [5] | 23 | M | Not performed | 4.7 cm | Vascular invasion, lymph node metastasis | Total thyroidectomy, vincristine, actinomycin D, cyclophosphamide etoposide and radiotherapy | under chemotherapy | N/A | |
Chan et al. [5] | 67 | F | Bethesda IV | 4.0 cm | Vascular invasion | Total thyroidectomy (2 steps), chemotherapy | 22 months ANED | N/A | |
Eloy et al. [12] | 24 | M | Not performed | 5.3 cm | Vascular invasion | Total thyroidectomy (2 steps), radioactive iodine | 13 years/ ANED | Positive | CEFTE |
Bishop et al. [8] | 19 | M | N/A | N/A | N/A | Surgery, additional therapy pending | 0 month | Focally positive (< 5%) | |
Bishop et al. [8] | 36 | F | N/A | N/A | N/A | Surgery, additional therapy pending | 0 month | Positive | |
Kabata et al. [15] | 34 | M | Small-cell malignant neoplasm, most likely of hematologic origin/ core needle bx: ewing sacoma | 6.0 cm | Not reported | Neo-adj. chemotherapy isthmolobectomy, cervical lymphadenectomy, radiotherapy (discontinued) | 18 months | N/A | |
Ongkeko et al. [20] | 36 | M | Suggestive of malignancy | 7.0 cm | Extrathyroidal extension, lymphovascular invasion, lymph node metastases | Total thyroidectomy, medial and right lateral neck dissection, chemotherapy | 2 years, ANED pancreatic metastasis treated by chemotherapy | N/A | |
Morlote et al. [21] | 20 | F | Suspicious for carcinoma | 4.0 cm | Not reported | Total thyroidectomy, chemotherapy, radiotherapy | 7 months ANED | Positive | |
Jones and Maleki [16] | 21 | M (transgender) | ALES | 7.0 cm | N/A | N/A | N/A (numerous lytic bone lesions) | Positive | |
Chikeka et al. [17] | 15 | F | Bethesda VI | 3.0 cm | Positive surgical margins | Total thyroidectomy, chemotherapy, radiotherapy | N/A | Positive | |
Taccogna et al. [10] | 40 | M | Bethesda V | 6.5 cm | Not reported | Total thyroidectomy | 6 months ANED | Positive | CEFTE |
Current case | 54 | F | Bethesda VI PDTC | 4.0 cm | Vascular invasion, positive surgical margins | Total thyroidectomy, chemotherapy, radiotherapy | 15 months ANED | Negative |
ANED alive, no evidence of disease, AWED alive with evidence of disease, N/A not available, CEFTE carcinoma of the thyroid with Ewing family tumor elements, ALES adamantinoma like Ewing sarcoma